FGFR1 and lymphoid neoplasm: Erdafitinib and pemigatinib, two TKIs targeting FGFR1-4 and FGFR1-3 respectively, obtained FDA approval for treating advanced urothelial cancer with FGFR2/3 genetic alterations and myeloid/lymphoid neoplasms with FGFR1 rearrangement [412].